Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]
It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.[2]
- Market Cap ₹ 2,092 Cr.
- Current Price ₹ 473
- High / Low ₹ 886 / 417
- Stock P/E 3,873
- Book Value ₹ 304
- Dividend Yield 0.00 %
- ROCE 6.01 %
- ROE 0.05 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -0.58% over past five years.
- Company has a low return on equity of -11.5% over last 3 years.
- Promoters have pledged 34.6% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | |
464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,077 | |
Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | 206 |
OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -7% | 16% |
2 | 12 | 27 | 29 | 16 | 22 | -185 | 8 | |
Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 |
Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 |
Profit before tax | 0 | 60 | 115 | 222 | -91 | -45 | -488 | 1 |
Tax % | -70% | 1% | 0% | 0% | -36% | -50% | 16% | -0% |
0 | 59 | 115 | 221 | -58 | -22 | -567 | 1 | |
EPS in Rs | 17.30 | 32.01 | 46.22 | -12.11 | -4.62 | -118.21 | 0.15 | |
Dividend Payout % | -0% | 22% | 5% | 11% | -0% | -49% | -0% | -0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -1% |
3 Years: | 0% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -66% |
3 Years: | 26% |
TTM: | 100% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -1% |
3 Years: | 9% |
1 Year: | 10% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -4% |
3 Years: | -11% |
Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 |
Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 898 | 1,054 |
633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 796 | |
425 | 466 | 346 | 404 | 383 | 386 | 406 | 342 | |
Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 |
1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,193 | |
CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 256 | 280 |
Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 |
663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 825 | 757 | |
Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
49 | 166 | 242 | 155 | -242 | 156 | 109 | 213 | |
-85 | -113 | -359 | -106 | -243 | -81 | -4 | -37 | |
68 | -23 | 97 | 92 | 334 | -113 | -106 | -180 | |
Net Cash Flow | 31 | 30 | -20 | 142 | -151 | -38 | -0 | -4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
Debtor Days | 184 | 76 | 63 | 109 | 141 | 136 | 99 | 93 |
Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 | 163 | 185 |
Days Payable | 420 | 127 | 132 | 156 | 154 | 142 | 142 | 145 |
Cash Conversion Cycle | 16 | 60 | 101 | 102 | 308 | 252 | 120 | 133 |
Working Capital Days | 107 | 34 | 67 | 118 | 251 | 213 | 126 | 127 |
ROCE % | 10% | 12% | 15% | -0% | 2% | -9% | 6% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
28 May - Solara Active Pharma Sciences Limited has informed regarding submission of Newspaper publication for transfer of unclaimed shares to IEPF account
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
28 May - Annual Secretarial Compliance Report for FY 2024-25 submitted by Solara Active Pharma.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
21 May - Q4 FY25 earnings call: missed revenue guidance, margin expansion, ibuprofen challenges, new leadership, CRAMS demerger plans.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 May - Solara Active Pharma Sciences Limited hereby informed on the newspaper publication made on May 16, 2025 wherein the Financial Results for the quarter and year …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
15 May - Audio recording of Q4 FY25 earnings call uploaded on company website for investor access.
Annual reports
Concalls
-
May 2025TranscriptPPTREC
-
Jan 2025Transcript PPT REC
-
Oct 2024Transcript PPT REC
-
Jul 2024TranscriptPPTREC
-
Jun 2024TranscriptPPTREC
-
Feb 2024TranscriptPPTREC
-
Nov 2023TranscriptPPTREC
-
Aug 2023TranscriptPPTREC
-
May 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022Transcript PPT
-
Jul 2021TranscriptPPT
-
Apr 2021Transcript PPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
May 2020Transcript PPT
-
Jan 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Jul 2018TranscriptPPT
Product Offerings
The company is a pure-play API manufacturer, offering a range of high-value commercial APIs and contract manufacturing services across 73+ countries. Its portfolio includes 60+ commercial APIs across key therapeutic segments, including anthelmintic, anti-malaria, anti-infective, etc. The top 10 molecules contribute to 84% of its total revenues. [1] [2] [3]